MANE
Veradermics, Inc
$129.74
+1.26 (+0.98%)
At close · Jul 2
Market Cap
$5.42B
Shares
41,778,687
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$129.74
Open$128.04
Day$122.88–130.86
52W$32.00–131.24
Avg vol 30d656K
Short int2.5M · 6.0% float · 6.0d
Short vol61%
Last earningsMay 12, 2026
DataFeb 2026–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 50-day avg
+27% above
−
RSI (14)
73 · overbought
+
MACD trend
positive
+
52-week position
98% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50/200-day averages unavailable
+
Institutional flow
1 of 80 funds reported for Jun 30 · net +72 sh shares · +1 new
◦
Insider flow
No net insider activity over 90 days
−
Short interest
5.97% of float · ▲ +5.5% MoM · 6.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
80 holders — 13F breadth
Fundamentals
Weak
−
EPS growth
−202% Y/Y
−
Free cash flow
$-71.6M
+
Balance sheet
net cash $21.8M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 50-day avg
+27% above
Bullish
RSI (14)
73 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
98% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
1 of 80 funds reported for Jun 30 · net +72 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.97% of float · ▲ +5.5% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
80 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $32
Now $130 · 98%
52-wk high $131
vs 50-day avg +27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MANE
this stock
Veradermics, Inc
|
$5.42B | — | — | — | 6.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MANE | +8.7% | +34.1% | — | +5.5% | — |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +7.3% | +35.4% | — | +5.8% | — |